JWH-x Synthetic Cannabinoids Cannabinoid Research

JWH-x Synthetic Cannabinoids Research Dashboard

57

Primary Studies

75

Related Studies

132

Total Studies

Clinical Studies

0

Clinical Meta-analyses

1

Double-blind human trials

1

Clinical human trials

Pre-Clinical Studies

6

Meta-analyses/Reviews

31

Animal studies

15

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 132 studies associated with JWH-x Synthetic Cannabinoids.

Here is a small sampling of JWH-x Synthetic Cannabinoids studies by title:


Components of the JWH-x Synthetic Cannabinoids Research Dashboard

  • Top medical conditions associated with JWH-x Synthetic Cannabinoids
  • Proven effects in clinical trials for JWH-x Synthetic Cannabinoids
  • Receptors associated with JWH-x Synthetic Cannabinoids
  • Individual study details for JWH-x Synthetic Cannabinoids

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - JWH-x Synthetic Cannabinoids

Description of JWH-x Synthetic Cannabinoids

This group of compounds is named after the organic chemist John William Huffman (1932–2022). Huffman and his team have developed over 400 synthetic cannabinoid compounds most of which are used to study the endocannabinoid system (ECS) and its potential for medicinal application.

However, members of the JWH series contain a number of compounds that have been used to produce "synthetic cannabinoids" such as "Spice", or "K2," which have been implemented in a number of well publicized overdoses and fatalities. As such, many of these compounds are banned in a number of countries such as China, Australia, or Ireland.

Due to their clinical relevance we focus here on two members of the JWH family i.e., JWH-018 and JWH-133.

Other members of this group that have been researched in the context of potential medical applications include: JWH-122 (full agonist at CB1 and CB2), which will also be listed in the primary and related study list accordingly.

Other Names:

JWH Family Synthetic Cannabinoids
JWH-018

Molecular Formula: C24H23NO

IUPAC Name: naphthalen-1-yl-(1-pentylindol-3-yl)methanone

JWH-133

Molecular Formula: C22H32O

IUPAC Name: (6aR,10aR)-6,6,9-trimethyl-3-(2-methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene

JWH-x Synthetic Cannabinoids Properties and Effects

JWH-018 may:
• Adversely affect male reproductive potential and testis histopathology (D. Mutluay et al., 2022)
• Induce psychosis (Susanna Every-Palmer, 2011; E. Theunissen et al., 2021)
• Induce anti-epileptic activities in a animal model of Dravet syndrome (A. Griffin et al. 2020)
• Increase heart rate, impaired critical tracking and memory (E. Theunissen et al., 2019)
• Induce seizure activities (O. Malyshevskaya et al., 2017)
• Produce hypothermia (S. Banister et al., 2015)
• Precipitate psychosis in vulnerable individuals (S. Every-Palmer 2011)
• Result in dependence (U. Zimmermann et al., 2009)

JWH-133 may:
• Increases Ectopic Ovarian Tumor Growth (H. Blanton et al., 2022)
• Induce apoptosis in gliomas (M. Falasca et al., 2021)
• Reduce uterine ischemia/reperfusion-induced damage (D. Kirmizi et al., 2021)
• Increase cerebral blood flow with potential relevance to diabetes (L. Van Hove et al., 2021)
• Promotes the first wave of in vitro spermatogenesis (L. Dumont et al., 2021)
• Induce seizure activity (Qiong Wu et al, 2020)
• Reduce inflammation and damage in brain, lung, liver and heart secondary to sepsis in the test animals (Murat Çakır et al., 2020)
• Reduce pro-inflammatory cytokines resulting in a reduction in blood pressure, heart rate, and renal sympathetic nerve activity in the test animals (He-Kai Shi et al., 2020)
• Have therapeutic potential for Substance Use Disorders (Ewa Galaj et al., 2019)
• Anti-inflammatory with potential relevance to lupus erythematosus and rheumatoid arthritis (J. Henriquez et al., 2019)
• Have acute, but not long-term, analgesic effects on virus infection-induced neuropathic pain (W. Sheng et al. 2019)
• Protect neurons against beta-amyloid peptides with relevance to Alzheimer's (Jingfu Zhao et al., 2020)
• Alleviated RSV-related lung pathology in the test animals (A. Tahamtan et al., 2018)
• Reduce neuropathy associated with type 2 diabetes (C. McDonnell et al., 2017)
• Reduce angiogenesis and inflammation associated with psoriasis (A. Norooznezhad et al., 2017)
• Reduce pulmonary fibrosis (Qiang Fu et al., 2017)
• Induce toxic effects on neuroblastoma cells (J. Wojcieszak et al., 2016)
• Reduce inflammation-induced liver injury (Sunil Tomar et al., 2015)
• Inhibit inflammation in an animal model of rheumatoid arthritis (S. Fukuda et al., 2014)
• Decrease HIV-1 reverse transcriptase activity (S. Ramirez et al., 2013)
• Induce anti-proliferative and anti-angiogenic potential against non-small lung cancer cells (B. Vidinský et al., 2012)
• Inhibit lung cancer metastasis (A. Preet et al., 2012)
• Prevent the development of skin and lung fibrosis (A. Servettaz et al., 2010)
• Reduce breast cancer (Z. Qamri et al., 2009; M. Caffarel et al., 2010)
• Induce cardio protective effects (F. Montecucco et al., 2009)
• Induce apoptosis in thyroid carcinoma (Y. Shi et al., 2008)
• Reduce inflammation in autoimmune uveoretinitis (Heping Xu et al., 2007)
• Be antitussive (H. Patel et al., 2003)
• Inhibit malignant tumors (C. Sánchez et al., 2001; M. Casanova et al., 2003)
• Ameliorate tremors and spasticity in an animal model of MS (D. Baker et al., 2000)

JWH-x Synthetic Cannabinoids Receptor Binding

Endocannabinoid System/JWH-018:
• CB1 full agonist with a Ki of ~9nM (M. Aung et al., 2000)
• CB2 full agonist with a Ki of ~3nM (M. Aung et al., 2000)

Endocannabinoidome (eCBome)/JWH-018:
• Increases 5-HT2A/2C receptor function in the brain (J. Elmore et al., 2018)

Endocannabinoid System/JWH-133:
• CB1 weak agonist with a Ki ~677nM (J. W. Hoffman et al., 1999)
• CB2 full agonist with a Ki ~3nM (J. W. Hoffman et al., 1999)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.